Treatment of CNS diseases with sGC stimulators
US11690828B2 · kind B2 · utility
0Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 7, 2017 |
| Grant date | Jul 4, 2023 |
| Priority date | — |
| Expiry date | Nov 7, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′,5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.